249 related articles for article (PubMed ID: 30824523)
21. A Comparison of Cell-Free DNA Isolation Kits: Isolation and Quantification of Cell-Free DNA in Plasma.
Sorber L; Zwaenepoel K; Deschoolmeester V; Roeyen G; Lardon F; Rolfo C; Pauwels P
J Mol Diagn; 2017 Jan; 19(1):162-168. PubMed ID: 27865784
[TBL] [Abstract][Full Text] [Related]
22. A Targeted Q-PCR-Based Method for Point Mutation Testing by Analyzing Circulating DNA for Cancer Management Care.
Thierry AR
Methods Mol Biol; 2016; 1392():1-16. PubMed ID: 26843041
[TBL] [Abstract][Full Text] [Related]
23. Preanalytical variables that affect the outcome of cell-free DNA measurements.
Ungerer V; Bronkhorst AJ; Holdenrieder S
Crit Rev Clin Lab Sci; 2020 Nov; 57(7):484-507. PubMed ID: 32393081
[TBL] [Abstract][Full Text] [Related]
24. Technical considerations for circulating tumor DNA detection in oncology.
Franczak C; Filhine-Tresarrieu P; Gilson P; Merlin JL; Au L; Harlé A
Expert Rev Mol Diagn; 2019 Feb; 19(2):121-135. PubMed ID: 30648442
[TBL] [Abstract][Full Text] [Related]
25. Circulating cell-free DNA for target quantification in hematologic malignancies: Validation of a protocol to overcome pre-analytical biases.
Soscia R; Della Starza I; De Novi LA; Ilari C; Ansuinelli M; Cavalli M; Bellomarino V; Cafforio L; Di Trani M; Cazzaniga G; Fazio G; Santoro A; Salemi D; Spinelli O; Tosi M; Terragna C; Robustelli V; Bellissimo T; Colafigli G; Breccia M; Chiaretti S; Di Rocco A; Martelli M; Guarini A; Del Giudice I; Foà R
Hematol Oncol; 2023 Feb; 41(1):50-60. PubMed ID: 36251440
[TBL] [Abstract][Full Text] [Related]
26. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
[TBL] [Abstract][Full Text] [Related]
27. Performance of Streck cfDNA Blood Collection Tubes for Liquid Biopsy Testing.
Medina Diaz I; Nocon A; Mehnert DH; Fredebohm J; Diehl F; Holtrup F
PLoS One; 2016; 11(11):e0166354. PubMed ID: 27832189
[TBL] [Abstract][Full Text] [Related]
28. Non-blood sources of cell-free DNA for cancer molecular profiling in clinical pathology and oncology.
Ponti G; Manfredini M; Tomasi A
Crit Rev Oncol Hematol; 2019 Sep; 141():36-42. PubMed ID: 31212145
[TBL] [Abstract][Full Text] [Related]
29. IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing.
Deans ZC; Butler R; Cheetham M; Dequeker EMC; Fairley JA; Fenizia F; Hall JA; Keppens C; Normanno N; Schuuring E; Patton SJ
Virchows Arch; 2019 Jun; 474(6):681-689. PubMed ID: 31028539
[TBL] [Abstract][Full Text] [Related]
30. Cell-free DNA as a post-treatment surveillance strategy: current status.
Burgener JM; Rostami A; De Carvalho DD; Bratman SV
Semin Oncol; 2017 Oct; 44(5):330-346. PubMed ID: 29580435
[TBL] [Abstract][Full Text] [Related]
31. "Future-Proofing" Blood Processing for Measurement of Circulating miRNAs in Samples from Biobanks and Prospective Clinical Trials.
Murray MJ; Watson HL; Ward D; Bailey S; Ferraresso M; Nicholson JC; Gnanapragasam VJ; Thomas B; Scarpini CG; Coleman N
Cancer Epidemiol Biomarkers Prev; 2018 Feb; 27(2):208-218. PubMed ID: 29254935
[No Abstract] [Full Text] [Related]
32. Fully automated, on-site isolation of cfDNA from whole blood for cancer therapy monitoring.
Kim CJ; Park J; Sunkara V; Kim TH; Lee Y; Lee K; Kim MH; Cho YK
Lab Chip; 2018 May; 18(9):1320-1329. PubMed ID: 29658031
[TBL] [Abstract][Full Text] [Related]
33. Circulating Cell-Free DNA and RNA Analysis as Liquid Biopsy: Optimal Centrifugation Protocol.
Sorber L; Zwaenepoel K; Jacobs J; De Winne K; Goethals S; Reclusa P; Van Casteren K; Augustus E; Lardon F; Roeyen G; Peeters M; Van Meerbeeck J; Rolfo C; Pauwels P
Cancers (Basel); 2019 Mar; 11(4):. PubMed ID: 30935089
[TBL] [Abstract][Full Text] [Related]
34. Isolation and Quantification of Plasma Circulating Tumor DNA from Melanoma Patients.
Marsavela G; Reid A; Gray ES; Calapre L
Methods Mol Biol; 2021; 2265():247-263. PubMed ID: 33704720
[TBL] [Abstract][Full Text] [Related]
35. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.
Merker JD; Oxnard GR; Compton C; Diehn M; Hurley P; Lazar AJ; Lindeman N; Lockwood CM; Rai AJ; Schilsky RL; Tsimberidou AM; Vasalos P; Billman BL; Oliver TK; Bruinooge SS; Hayes DF; Turner NC
Arch Pathol Lab Med; 2018 Oct; 142(10):1242-1253. PubMed ID: 29504834
[TBL] [Abstract][Full Text] [Related]
36. Results of the first external quality assessment scheme (EQA) for isolation and analysis of circulating tumour DNA (ctDNA).
Haselmann V; Ahmad-Nejad P; Geilenkeuser WJ; Duda A; Gabor M; Eichner R; Patton S; Neumaier M
Clin Chem Lab Med; 2018 Jan; 56(2):220-228. PubMed ID: 28841569
[TBL] [Abstract][Full Text] [Related]
37. Collection of cell-free DNA for genomic analysis of solid tumors in a clinical laboratory setting.
Raymond CK; Hernandez J; Karr R; Hill K; Li M
PLoS One; 2017; 12(4):e0176241. PubMed ID: 28448587
[TBL] [Abstract][Full Text] [Related]
38. A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.
Volckmar AL; Sültmann H; Riediger A; Fioretos T; Schirmacher P; Endris V; Stenzinger A; Dietz S
Genes Chromosomes Cancer; 2018 Mar; 57(3):123-139. PubMed ID: 29205637
[TBL] [Abstract][Full Text] [Related]
39. Optimizing the yield and utility of circulating cell-free DNA from plasma and serum.
Xue X; Teare MD; Holen I; Zhu YM; Woll PJ
Clin Chim Acta; 2009 Jun; 404(2):100-4. PubMed ID: 19281804
[TBL] [Abstract][Full Text] [Related]
40. Cell-Free DNA as a Diagnostic Blood-Based Biomarker for Colorectal Cancer: A Systematic Review.
Petit J; Carroll G; Gould T; Pockney P; Dun M; Scott RJ
J Surg Res; 2019 Apr; 236():184-197. PubMed ID: 30694754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
